In terms of infection risk, Etrasimod appears comparable to other S1P modulators: slight increases in mostly mild infections have been noted (e.g., nasopharyngitis, sinusitis), but serious opportunistic infections remain rare (Vermeire et al., 2025). Here, MBTPS1 is linked to infection.